Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 8/20 | 0.48 |
| ▸ | JAK2 | O60674 | 5/20 | 0.48 |
| ▸ | JAK1 | P23458 | 6/20 | 0.47 |
| ▸ | PRKCI | P41743 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | CDK8 | P49336 | 3/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 4/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | MELK | Q14680 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL100093 | 1.00 | JAK3 (0.48) | JAK3JAK2JAK1PRKCIBTK | |
| Trifluoroacetic Acid SCHEMBL4092161 | 0.94 | JAK3 (0.43) | JAK3JAK2JAK1PRKCIBTK | |
| SCHEMBL29540587 | 0.85 | JAK3 (0.48) | JAK3JAK2JAK1BTKCDK8 | |
| SCHEMBL101336 | 0.85 | JAK3 (0.48) | JAK3JAK2JAK1BTKCDK8 | |
| SCHEMBL100532 | 0.80 | PRKCI (0.51) | JAK3JAK2JAK1PRKCICDK8 | |
| Trifluoroacetic Acid SCHEMBL4092015 | 0.80 | JAK3 (0.44) | JAK3JAK2JAK1BTKTYK2 | |
| SCHEMBL4092166 | 0.80 | PRKCI (0.39) | JAK3PRKCICDK8BRAFGRM4 | |
| SCHEMBL98775 | 0.79 | GRM5 (0.56) | JAK3PRKCIBRAFGRM4 | |
| Trifluoroacetic Acid SCHEMBL4082559 | 0.78 | PRKCI (0.43) | JAK3JAK2JAK1PRKCICDK8 | |
| SCHEMBL4099697 | 0.78 | PRKCI (0.46) | JAK3JAK1PRKCIBRAFGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3838903-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2023-11-22 | — | — | EP | disclosed |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2022-12-15 | — | — | US | disclosed |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | JAK3 1/4885JAK2 3/4885JAK1 2/4885 |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | JAK3 1/4885JAK2 3/4885JAK1 2/4885 |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | JAK3 1/4885JAK2 3/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.